{"id":9359,"date":"2013-10-02T02:47:16","date_gmt":"2013-10-02T06:47:16","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=9359"},"modified":"2013-10-02T06:49:48","modified_gmt":"2013-10-02T10:49:48","slug":"achillion-pharmaceuticals-inc-nasdaqachn-shares-decline-by-12-25","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/achillion-pharmaceuticals-inc-nasdaqachn-shares-decline-by-12-25-9359","title":{"rendered":"Achillion Pharmaceuticals, Inc (NASDAQ:ACHN) shares decline by 12.25%"},"content":{"rendered":"<p style=\"text-align: justify;\">Boston, MA 10\/02\/2013 (wallstreetpr) &#8211;\u00a0In Tuesday\u2019s trading, Achillion Pharmaceuticals, Inc (NASDAQ:ACHN) dropped by 12.25%. The shares opened at a price of $2.99, climbed to an intraday high of $3.04 and dipped to a close of $2.65. Approximately 12.20 million shares were traded on Tuesday while an average volume of 2.52 million shares were traded over a 30 day period. The 52-week low of the company\u2019s shares is $2.62 and its 52-week high is $11.36. The company has a market capitalization of $256.10 million.<\/p>\n<p style=\"text-align: justify;\"><strong>About the company<\/strong><\/p>\n<p style=\"text-align: justify;\">Achillion Pharmaceuticals, Inc (NASDAQ:ACHN) was incorporated on 17 August 1998. It is a bio-pharma company that focuses on discovering, developing and commercializing of treatments that are used for infectious diseases. Achillion Pharmaceuticals, Inc (NASDAQ:ACHN) is involved in developing antivirals that are used to treat patients suffering from chronic hepatitis C infection.<\/p>\n<p style=\"text-align: justify;\">It also develops antibacterials that are used to treat various resistant-bacterial infections. It focuses on developing its 4 drug candidates that are used in HCV treatment: 1) ACH-1625, which is a NS3 protease-inhibitor, 2) ACH-2684, which is a NS3 protease-inhibitor, 3) ACH-2928, a NS5A-inhibitor, and 4) ACH-3102, a NS5A-inhibitor.<\/p>\n<p style=\"text-align: justify;\">Achillion Pharmaceuticals, Inc (NASDAQ:ACHN) is also evaluating ACH-1625. This is a protease-inhibitor for the treatment of chronic hepatitis C and is in a phase IIA clinical-trial to assess its safety, tolerability, pharmacokinetic-properties and efficacy in HCV-infected subjects.<\/p>\n<p style=\"text-align: justify;\"><strong>Other drug candidates<\/strong><\/p>\n<p style=\"text-align: justify;\">Achillion Pharmaceuticals, Inc (NASDAQ:ACHN) has established numerous other product candidates in the pipeline. It is seeking appropriate collaborative-partners for these products. It does not have required resources for ACH-2881 and ACH-702 for drug-resistant bacterial infections and the drug called elvucitabine for HIV infection.<\/p>\n<p style=\"text-align: justify;\"><strong>Competitors<\/strong><\/p>\n<p style=\"text-align: justify;\">Achillion Pharmaceuticals, Inc (NASDAQ:ACHN) competes with Merck, Roche, Celgene, Vertex, Pfizer, Abbott, Boehringer Ingelheim, Astra-Zeneca, Novartis, Human Genome Sciences. Its other competitors are Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Idenix, Enanta, Presidio, Johnson &amp; Johnson, Medivir and Valeant.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Boston, MA 10\/02\/2013 (wallstreetpr) &#8211;\u00a0In Tuesday\u2019s trading, Achillion Pharmaceuticals, Inc (NASDAQ:ACHN) dropped by 12.25%. The shares opened at a price of $2.99, climbed to an [&hellip;]<\/p>\n","protected":false},"author":9,"featured_media":9360,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[2990,3133,2991],"stock_ticker":[],"class_list":["post-9359","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-achillion-pharmaceuticals-inc-nasdaqachn","tag-achillion-pharmaceuticals-inc","tag-nasdaqachn","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Achillion Pharmaceuticals, Inc (NASDAQ:ACHN) shares decline by 12.25% - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/achillion-pharmaceuticals-inc-nasdaqachn-shares-decline-by-12-25-9359\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Achillion Pharmaceuticals, Inc (NASDAQ:ACHN) shares decline by 12.25% - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Boston, MA 10\/02\/2013 (wallstreetpr) &#8211;\u00a0In Tuesday\u2019s trading, Achillion Pharmaceuticals, Inc (NASDAQ:ACHN) dropped by 12.25%. The shares opened at a price of $2.99, climbed to an [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/achillion-pharmaceuticals-inc-nasdaqachn-shares-decline-by-12-25-9359\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2013-10-02T06:47:16+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2013-10-02T10:49:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/10\/shutterstock_95565316_0.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"768\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Van Bettauer\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Van Bettauer\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/achillion-pharmaceuticals-inc-nasdaqachn-shares-decline-by-12-25-9359#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/achillion-pharmaceuticals-inc-nasdaqachn-shares-decline-by-12-25-9359\"},\"author\":{\"name\":\"Van Bettauer\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/086385e1495fa1df08b6dabd5d8a4e5d\"},\"headline\":\"Achillion Pharmaceuticals, Inc (NASDAQ:ACHN) shares decline by 12.25%\",\"datePublished\":\"2013-10-02T06:47:16+00:00\",\"dateModified\":\"2013-10-02T10:49:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/achillion-pharmaceuticals-inc-nasdaqachn-shares-decline-by-12-25-9359\"},\"wordCount\":307,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/achillion-pharmaceuticals-inc-nasdaqachn-shares-decline-by-12-25-9359#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/10\/shutterstock_95565316_0.jpg\",\"keywords\":[\"Achillion Pharmaceuticals Inc (NASDAQ:ACHN)\",\"Achillion Pharmaceuticals Inc.\",\"NASDAQ:ACHN\"],\"articleSection\":[\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/achillion-pharmaceuticals-inc-nasdaqachn-shares-decline-by-12-25-9359#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/achillion-pharmaceuticals-inc-nasdaqachn-shares-decline-by-12-25-9359\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/achillion-pharmaceuticals-inc-nasdaqachn-shares-decline-by-12-25-9359\",\"name\":\"Achillion Pharmaceuticals, Inc (NASDAQ:ACHN) shares decline by 12.25% - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/achillion-pharmaceuticals-inc-nasdaqachn-shares-decline-by-12-25-9359#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/achillion-pharmaceuticals-inc-nasdaqachn-shares-decline-by-12-25-9359#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/10\/shutterstock_95565316_0.jpg\",\"datePublished\":\"2013-10-02T06:47:16+00:00\",\"dateModified\":\"2013-10-02T10:49:48+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/achillion-pharmaceuticals-inc-nasdaqachn-shares-decline-by-12-25-9359#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/achillion-pharmaceuticals-inc-nasdaqachn-shares-decline-by-12-25-9359\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/achillion-pharmaceuticals-inc-nasdaqachn-shares-decline-by-12-25-9359#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/10\/shutterstock_95565316_0.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/10\/shutterstock_95565316_0.jpg\",\"width\":1024,\"height\":768},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/achillion-pharmaceuticals-inc-nasdaqachn-shares-decline-by-12-25-9359#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Achillion Pharmaceuticals, Inc (NASDAQ:ACHN) shares decline by 12.25%\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/086385e1495fa1df08b6dabd5d8a4e5d\",\"name\":\"Van Bettauer\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/96de7d8946529978255828dc0fee029f894f4355641bdd9b5d409917697f57b1?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/96de7d8946529978255828dc0fee029f894f4355641bdd9b5d409917697f57b1?s=96&d=mm&r=g\",\"caption\":\"Van Bettauer\"},\"description\":\"Van Bettauer is a financial aficionado from Vancouver, British Columbia. He currently studies at UBC, pursuing a Bachelors of Science degree. Van has been freelance writing for many years, specializing in copywriting, report writing and article writing. The combination of his scientific studies and writing experience brings a new and fresh perspective to the financial world. Visit Bettauer's Google+ page at the following address: https:\/\/plus.google.com\/100770875710593766367\/posts\",\"sameAs\":[\"https:\/\/cablemanpro.com\/wallstreetpr\"],\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/van-bettauer\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Achillion Pharmaceuticals, Inc (NASDAQ:ACHN) shares decline by 12.25% - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/achillion-pharmaceuticals-inc-nasdaqachn-shares-decline-by-12-25-9359","og_locale":"en_US","og_type":"article","og_title":"Achillion Pharmaceuticals, Inc (NASDAQ:ACHN) shares decline by 12.25% - Wall Street PR","og_description":"Boston, MA 10\/02\/2013 (wallstreetpr) &#8211;\u00a0In Tuesday\u2019s trading, Achillion Pharmaceuticals, Inc (NASDAQ:ACHN) dropped by 12.25%. The shares opened at a price of $2.99, climbed to an [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/achillion-pharmaceuticals-inc-nasdaqachn-shares-decline-by-12-25-9359","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2013-10-02T06:47:16+00:00","article_modified_time":"2013-10-02T10:49:48+00:00","og_image":[{"width":1024,"height":768,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/10\/shutterstock_95565316_0.jpg","type":"image\/jpeg"}],"author":"Van Bettauer","twitter_misc":{"Written by":"Van Bettauer","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/achillion-pharmaceuticals-inc-nasdaqachn-shares-decline-by-12-25-9359#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/achillion-pharmaceuticals-inc-nasdaqachn-shares-decline-by-12-25-9359"},"author":{"name":"Van Bettauer","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/086385e1495fa1df08b6dabd5d8a4e5d"},"headline":"Achillion Pharmaceuticals, Inc (NASDAQ:ACHN) shares decline by 12.25%","datePublished":"2013-10-02T06:47:16+00:00","dateModified":"2013-10-02T10:49:48+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/achillion-pharmaceuticals-inc-nasdaqachn-shares-decline-by-12-25-9359"},"wordCount":307,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/achillion-pharmaceuticals-inc-nasdaqachn-shares-decline-by-12-25-9359#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/10\/shutterstock_95565316_0.jpg","keywords":["Achillion Pharmaceuticals Inc (NASDAQ:ACHN)","Achillion Pharmaceuticals Inc.","NASDAQ:ACHN"],"articleSection":["Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/achillion-pharmaceuticals-inc-nasdaqachn-shares-decline-by-12-25-9359#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/achillion-pharmaceuticals-inc-nasdaqachn-shares-decline-by-12-25-9359","url":"https:\/\/cablemanpro.com\/wallstreetpr\/achillion-pharmaceuticals-inc-nasdaqachn-shares-decline-by-12-25-9359","name":"Achillion Pharmaceuticals, Inc (NASDAQ:ACHN) shares decline by 12.25% - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/achillion-pharmaceuticals-inc-nasdaqachn-shares-decline-by-12-25-9359#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/achillion-pharmaceuticals-inc-nasdaqachn-shares-decline-by-12-25-9359#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/10\/shutterstock_95565316_0.jpg","datePublished":"2013-10-02T06:47:16+00:00","dateModified":"2013-10-02T10:49:48+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/achillion-pharmaceuticals-inc-nasdaqachn-shares-decline-by-12-25-9359#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/achillion-pharmaceuticals-inc-nasdaqachn-shares-decline-by-12-25-9359"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/achillion-pharmaceuticals-inc-nasdaqachn-shares-decline-by-12-25-9359#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/10\/shutterstock_95565316_0.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2013\/10\/shutterstock_95565316_0.jpg","width":1024,"height":768},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/achillion-pharmaceuticals-inc-nasdaqachn-shares-decline-by-12-25-9359#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"Achillion Pharmaceuticals, Inc (NASDAQ:ACHN) shares decline by 12.25%"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/086385e1495fa1df08b6dabd5d8a4e5d","name":"Van Bettauer","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/96de7d8946529978255828dc0fee029f894f4355641bdd9b5d409917697f57b1?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/96de7d8946529978255828dc0fee029f894f4355641bdd9b5d409917697f57b1?s=96&d=mm&r=g","caption":"Van Bettauer"},"description":"Van Bettauer is a financial aficionado from Vancouver, British Columbia. He currently studies at UBC, pursuing a Bachelors of Science degree. Van has been freelance writing for many years, specializing in copywriting, report writing and article writing. The combination of his scientific studies and writing experience brings a new and fresh perspective to the financial world. Visit Bettauer's Google+ page at the following address: https:\/\/plus.google.com\/100770875710593766367\/posts","sameAs":["https:\/\/cablemanpro.com\/wallstreetpr"],"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/van-bettauer"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/9359","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/9"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=9359"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/9359\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/9360"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=9359"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=9359"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=9359"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=9359"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}